Related Experiment Video
Updated: Feb 4, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Stroke prevention in atrial fibrillation: State of the art
Yan-Guang Li1, Gregory Y H Lip2
1Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom; Liverpool Centre for Cardiovascular Science, University of Liverpool, United Kingdom; Department of Cardiology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, China.
Insights
Identifying low-risk patients with atrial fibrillation (AF) is key. The CHA2DS2-VASc score helps omit unnecessary oral anticoagulation (OAC) therapy, improving patient outcomes and reducing treatment burdens.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Stroke prevention is crucial for managing atrial fibrillation (AF).
- Current methods for identifying high-risk AF patients have limitations.
- Accurate risk stratification guides the decision for oral anticoagulation (OAC).
Purpose of the Study:
- To evaluate the effectiveness of the CHA2DS2-VASc score in identifying low-risk AF patients.
- To discuss the role of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in AF management.
- To highlight the importance of OAC adherence and quality for optimal outcomes.
Main Methods:
- Utilized the CHA2DS2-VASc scoring system for risk stratification in AF patients.
- Compared the efficacy, safety, and convenience of NOACs and VKAs.
- Reviewed factors affecting OAC adherence and quality of use.
Main Results:
- The CHA2DS2-VASc score effectively identifies very low-risk AF patients (score 0 in males, 1 in females) who may not require OAC.
- NOACs offer advantages in efficacy, safety, and convenience over VKAs.
- VKA therapy can be effective with good anticoagulation control (TTR >70%).
- OAC use remains suboptimal in certain regions, necessitating improved adherence and quality.
Conclusions:
- The CHA2DS2-VASc score is a valuable tool for de-prescribing OAC in low-risk AF patients.
- Optimizing OAC therapy, including the choice between NOACs and VKAs, is essential for stroke prevention.
- Improving long-term adherence and quality of OAC use is critical for better patient outcomes in AF management.
Abstract:
Stroke prevention is the cornerstone of the management of patients with atrial fibrillation (AF). Individual stroke risk stratification is generally the first step of deciding whether oral anticoagulation (OAC) will benefit patients with AF. Given that existing approaches to the prediction of 'high-risk' subjects are of limited value, the initial focus should be the identification of 'low-risk' patients who do not need antithrombotic therapy. For this, the CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥ 75 [2 points], diabetes mellitus, previous stroke/transient ischemic attack [2 points], vascular disease, age 65-74, female sex) performs well in identifying really low-risk patients (score of 0 in males or 1 in females), for whom OAC can be omitted. The approach to AF management has changed, with the non-vitamin K antagonist oral anticoagulants (NOACs) providing relatively better efficacy, safety and convenience compared with the traditional vitamin K antagonists (VKAs). The latter drugs are performing well, if attention is directed towards good quality anticoagulation control, as reflected by a time in therapeutic range (TTR) >70%. Nevertheless, OAC use remains suboptimal especially in some regions, such as Asia and Africa. Long-term adherence and quality of OAC use need to be maintained for better outcomes in patients with AF.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Cancer Prevention
Some...
Prevention of Further Absorption of Poison
Preventive Healthcare Services

